Porton Down, UK, 1 December 2009 - GW Pharmaceuticals plc (AIM: GWP) is pleased to announce the appointment, with immediate effect, of Piper Jaffray Ltd as Nominated Advisor and broker to the Company.... more
Porton Down, UK, 25 November 2009: GW Pharmaceuticals plc (GWP:AIM) announces that it has completed recruitment into its Sativex® Phase II/III cancer pain trial. This study is being carried out in co... more
Porton Down, UK, 25 November 2009: GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new cannabinoid medicines, including Sativex®, announces its preliminary results for ... more
Porton Down, UK, 23 November 2009: GW Pharmaceuticals plc (GWP:AIM) announces that the results of a clinical study of Sativex® in the treatment of cancer pain have been published in the highly-regarde... more
GW Pharmaceuticals plc (AIM: GWP) announces that results from two clinical studies of Sativex® were presented at Europe's leading multiple sclerosis (MS) conference, the 25th Congress of the European ... more
GW Pharmaceuticals plc (AIM: GWP) announces that its Managing Director, Justin Gover, will be presenting at the Rodman and Renshaw Annual Global Investment Conference in New York on Thursday, Septembe... more
GW Pharmaceuticals plc (GWP:AIM), the developer and manufacturer of a range of new cannabinoid medicines, including Sativex, today announces that it has signed an agreement with funds controlled by Gr... more
GW Pharmaceuticals plc (GWP:AIM) today announces that it has passed a Good Manufacturing Practice (GMP) inspection by the UK regulatory authority of its new in-house commercial manufacturing facility ... more
GW Pharmaceuticals plc (GWP:AIM) today announces that it has entered into an exclusive strategic alliance with Professor Mike Cawthorne and the Clore Laboratory, University of Buckingham, focusing on ... more
GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new cannabinoid medicines, including Sativex, announces its interim results for the six months ended 31 March 2009.... more
GW Pharmaceuticals plc (GWP:AIM) today announces that it has filed a regulatory submission for Sativex for the treatment of spasticity due to Multiple Sclerosis. This submission follows the recent ann... more
GW Pharmaceuticals plc (GWP:AIM) today announces that it has received confirmation from its licensing partner, Laboratorios Almirall S.A., that it will pay to GW a milestone payment of GBP 8 million. ... more
GW Phase III Spasticity Results - Analyst Presentation GW Pharmaceuticals plc hosted todays Phase III Spasticity Results Analyst Presentation on Wednesday 11th March 2009 at 2:30pm.... more
GW Pharmaceuticals plc (GWP:AIM) today announces positive preliminary results from a pivotal Phase III double-blind randomised placebo-controlled study of Sativex in patients with spasticity due to M... more
GW Pharmaceuticals plc (GWP:AIM) announces positive results from a placebo-controlled randomized withdrawal study of Sativex® in patients with spasticity due to Multiple Sclerosis (MS). This study was... more
